Davis Polk & Wardwell, Zhong Lun Law Firm and have advised Chinese biopharmaceutical company Zai Lab’s on its $761 million secondary listing on the mainboard of the Hong Kong Stock Exchange, with Simpson Thacher & Bartlett and Commerce & Finance Law Offices advising the underwriters.
Zai Lab’s offering follows Yum China Holdings’ recent HKSE cross-listing. Both companies first listed shares on the NYSE.
Travers Thorp Alberga advised Zai Lab on the offshore aspects of the transaction.
To contact the editorial team, please email ALBEditor@thomsonreuters.com.